{"organizations": [], "uuid": "75b838043b0021b03d345352643338979ca3d732", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biogenand-abbvie-announcethe-volun/brief-biogenand-abbvie-announcethe-voluntaryworldwide-withdrawal-of-marketing-authorizations-forzinbryta-idUSFWN1QK0P1", "country": "US", "domain_rank": 408, "title": "BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-02T12:17:00.000+02:00", "replies_count": 0, "uuid": "75b838043b0021b03d345352643338979ca3d732"}, "author": "", "url": "https://www.reuters.com/article/brief-biogenand-abbvie-announcethe-volun/brief-biogenand-abbvie-announcethe-voluntaryworldwide-withdrawal-of-marketing-authorizations-forzinbryta-idUSFWN1QK0P1", "ord_in_thread": 0, "title": "BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta", "locations": [], "entities": {"persons": [], "locations": [{"name": "zinbryta", "sentiment": "none"}], "organizations": [{"name": "biogen", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "thdrawal of marketing authorizations for zinbryta reuters staff", "sentiment": "none"}, {"name": "abbvie inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2, 2018 / 10:18 AM / in 10 minutes BRIEF-Biogen And Abbvie Announce The Voluntary Worldwide Withdrawal Of Marketing Authorizations For Zinbryta Reuters Staff 1 Min Read March 2 (Reuters) - Abbvie Inc: * BIOGEN AND ABBVIE ANNOUNCE THE VOLUNTARY WORLDWIDE WITHDRAWAL OF MARKETING AUTHORIZATIONS FOR ZINBRYTA® (DACLIZUMAB) FOR RELAPSING MULTIPLE SCLEROSIS * ABBVIE INC - EMA HAS INITIATED AN ARTICLE 20 REFERRAL PROCEDURE FOLLOWING REPORTS OF INFLAMMATORY ENCEPHALITIS AND MENINGOENCEPHALITIS * ABBVIE - ‍BIOGEN WILL CONTINUE TO WORK WITH REGULATORY AUTHORITIES & WITH HEALTHCARE PROVIDERS IN THEIR MANAGEMENT OF ZINBRYTA PATIENTS​ * ABBVIE - GIVEN NATURE OF ADVERSE EVENTS REPORTED, CHARACTERIZING PROFILE OF ZINBRYTA TO NOT BE POSSIBLE GOING AHEAD WITH LIMITED PATIENTS BEING TREATED * ABBVIE INC - BIOGEN BELIEVES VOLUNTARY WORLDWIDE WITHDRAWAL OF ZINBRYTA“IS IN BEST INTEREST OF PATIENTS” Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-02T12:17:00.000+02:00", "crawled": "2018-03-02T12:41:46.002+02:00", "highlightTitle": ""}